Shares of Cantel Medical Co. (NYSE:CMD) have earned an average broker rating score of 2.25 (Buy) from the four brokers that provide coverage for the stock, Zacks Investment Research reports. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company.
Brokerages have set a twelve-month consensus price target of $135.00 for the company and are anticipating that the company will post $0.59 EPS for the current quarter, according to Zacks. Zacks has also given Cantel Medical an industry rank of 173 out of 265 based on the ratings given to its competitors.
Large investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its position in shares of Cantel Medical by 12.9% during the third quarter. Russell Investments Group Ltd. now owns 24,818 shares of the company’s stock worth $2,338,000 after acquiring an additional 2,834 shares in the last quarter. Legal & General Group Plc increased its position in shares of Cantel Medical by 3.1% during the third quarter. Legal & General Group Plc now owns 71,989 shares of the company’s stock worth $6,774,000 after acquiring an additional 2,135 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of Cantel Medical by 26.8% during the third quarter. JPMorgan Chase & Co. now owns 37,480 shares of the company’s stock worth $3,408,000 after acquiring an additional 7,917 shares in the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Cantel Medical by 4.8% during the third quarter. Schwab Charles Investment Management Inc. now owns 198,741 shares of the company’s stock worth $18,716,000 after acquiring an additional 9,021 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its position in shares of Cantel Medical by 0.5% during the third quarter. Dimensional Fund Advisors LP now owns 977,435 shares of the company’s stock worth $92,042,000 after acquiring an additional 5,080 shares in the last quarter. 85.19% of the stock is owned by hedge funds and other institutional investors.
Cantel Medical (NYSE:CMD) last issued its earnings results on Thursday, March 8th. The company reported $0.59 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.58 by $0.01. Cantel Medical had a net margin of 10.92% and a return on equity of 17.18%. The firm had revenue of $213.03 million during the quarter, compared to the consensus estimate of $210.60 million. research analysts predict that Cantel Medical will post 2.5 EPS for the current fiscal year.
About Cantel Medical
Cantel Medical Corp. provides infection prevention products and services for the healthcare market worldwide. The company operates through four segments: Endoscopy, Water Purification and Filtration, Healthcare Disposables, and Dialysis. The Endoscopy segment offers automated endoscope reprocessing systems; detergents; leak testing and manual cleaning products; storage cabinets; transport systems; mobile medical carts; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid and flexible endoscopes, and other instrumentation; cleaning and disinfecting reusable components used in gastrointestinal endoscopy procedures; and technical maintenance services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cantel Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical and related companies with MarketBeat.com's FREE daily email newsletter.